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Background
Cancers result from the accumulation of various types of DNA mutations including point mutations, indels, large scale copy number aberrations (CNA), and structural variations [1] . During tumor development, in addition to mutations that confer functional advantages to tumor cells (i.e. driver mutations) [2] , a large number of passenger mutations with no or little functional impact may arise, confounding our ability to identify the key events in oncogenesis for understanding and treating cancers [3] .
Recent large scale cancer genome sequencing efforts such as The Cancer Genome Atlas (TCGA) [4] , International Cancer Genome Consortium (ICGC) [5] and other studies (e.g. [6, 7] ) have harnessed technological advances in DNA/RNA sequencing to provide comprehensive mutation catalogs and associated omics profiles in tumors. These compendiums provide a rich resource for the development of integrative cancer driver prediction methods [8] [9] [10] . In addition, they further highlight the challenges that still remain in driver prediction. In particular, due to the heterogeneity of cancer types, often few frequently mutated (and likely driver) genes were identified in these studies with many more genes being rarely mutated and thus indistinguishable from noise due to passenger mutations [11] [12] [13] . Despite this, the ability to identify cancer drivers may be key for improved targeted therapy [14] [15] [16] . For example, breast cancer patients with ERBB2 driver mutations can respond successfully to the ERBB2 inhibitor trastuzumab [17] , but similar therapy may also benefit patients with other cancers where ERBB2 mutations are rare [18] . After the initial wave of large-scale cancer studies, different cohorts of patients continue to be sequenced with more distinct phenotypes (e.g. previously unprofiled disease sites or disease states such as tumors characterized by primary or acquired drug resistance). In the growing paradigm of precision oncology individual patients are also sequenced either broadly (whole exome) or with targeted sequencing panels of genes selected by above studies and existing knowledge about the patient's disease and available treatments, in order to gain insights into biology and to match the right patient to the right drug at the right time. There is thus a deep biological and clinical need to identify the mutation that drives the tumor of a single patient.
Due to its biological and practical importance, a range of different approaches have been proposed for inferring the impact of mutations on genes and their likely role in cancer. These methods differ widely in the information they require as input (e.g. point mutations, indels, CNAs, expression data etc.) and in the models/assumptions that they use [19] [20] [21] . For example, many methods are based on using information about protein structure and evolution to detect point mutations that may have a functional impact in general (FI) [22] [23] [24] [25] , or specifically in the context of cancer (FIC) [26] [27] [28] .
These methods predict functional/driver mutations in each sample independently and their relative strengths have been studied in previous work [29, 30] . With the availability of large and heterogeneous cancer genomic datasets, newer methods have focused on cohort based analysis to search for biases in mutation frequency indicative of positive selection in driver genes (CBA) [31] [32] [33] [34] [35] [36] (compared in [37] ), or mined for mutation-expression correlations to highlight driver CNAs (MEC) [38] [39] [40] (jointly evaluated in [41] ). Other approaches have used mutual exclusivity of driver mutations to identify them in a large cohort of patients [42, 43] . Finally, a few methods have sought to incorporate information about gene interaction networks in their analysis with the aim of providing more sensitive predictions [44, 45] , or to enable driver prediction based on integrative analysis of genomic and transcriptomic data (INA) [8] [9] [10] .
Despite the diversity of driver prediction methods, a comprehensive evaluation of the strengths and weaknesses of different classes of methods on a diverse range of cancer types has not been conducted. We sought to address this by evaluating the performance of a panel of 18 different computational methods, covering a wide variety of models and input data types, on >3,400 tumor datasets from 15 TCGA cancer types. Methods were evaluated systematically for their concordance with gold-standard lists of driver and passenger genes, for their robustness to noise in the input, for their utility for working with data from small patient cohorts and for their ability to provide accurate and actionable patient-specific predictions for precision medicine applications. The overall predictive power for driver events was found to be moderate, highlighting the need for novel approaches and improved methods. Additionally, predictions from different classes of methods were found to be orthogonal to each other, motivating the development of a consensus-based approach (ConsensusDriver) to increase sensitivity and specificity of driver predictions across cancer types.
Consensus-based approaches such as ConsensusDriver provide a systematic way to combine the strengths of different driver prediction algorithms in building an analytical toolbox for precision oncology.
Results
Different cancer types represent diverse driver prediction challenges
For the purpose of this study, we selected 15 different cancer types from TCGA for which exome sequencing, copy number and expression data (RNA-seq or arrays) were available (BLCA: Bladder CNAs (GBM). In addition, certain cancer types exhibited a bimodal distribution for mutational burden (READ, COAD, PRAD and KIRC) and this could impact the distributional assumptions of some methods. The distribution of mutation frequencies across genes also showed high variation between cancer types (Supplementary Figure 1) . For example, while LUSC and OV have many genes with mutation frequency above 25%, THCA has only 3 genes with frequency above 5%, potentially impacting the sensitivity of methods that are dependent on mutation frequency for driver prediction (Figure 1b) . We additionally noted that most tumors exhibited both point mutations and Figure 2a) and thus methods that take only a subset of mutation types as input may be at a disadvantage in terms of sensitivity (e.g. FI and FIC methods which only consider missense variants; Supplementary Figure 2b) .
CNAs (Supplementary
In terms of driver prediction methods, we attempted to be as comprehensive as possible, though some methods had to be excluded due to feasibility issues (see Methods). In total, we evaluated 18 methods that could be used for driver prediction (Figure 1b) , classifying these methods into (i) methods that belong to the Functional Impact (FI) category (primarily designed to identify function altering mutations but have been used for predicting drivers [29, 30, 46] ) such as SIFT [22] , PolyPhen2 (PP2) [23] , MutationTaster (MT) [24] and MutationAssessor (MA) [25] , (ii) methods that tailor this idea to cancer by learning specific models (Functional Impact in Cancer; FIC) such as CHASM [26] , transFIC (TF) [27] and fathmm (FH) [28] , (iii) methods that use cohort based analysis to detect signals of positive selection (CBA) such as ActiveDriver (AD) [36] , MutSigCV (MCV) [31] , MuSiC (MUS) [32] , OncodriveCLUST (OCL) [33] and OncodriveFM (OF) [34] (all point mutation based), (iv) methods that integrate mutation data with transcriptomic data by looking for mutation-expression correlations (MEC) such as Conexic (CON) [38] , OncodriveCIS (OCI) [39] and S2N [40] , and finally (v) methods that use information from gene/protein interaction networks to analyze the effect of mutations such as NetBox (NB) [44] , HotNet2 (HN2) [45] , DriverNet (DN) [8] , DawnRank (DR) [9] and OncoIMPACT (OI) [10] . We evaluated these 18 methods in predicting cancer drivers in patient cohorts and in individual patients.
Driver gene prediction identifies many novel drivers but sensitivity is still a bottleneck
To evaluate the ability of various driver prediction methods to accurately differentiate between driver and passenger genes in a dataset, we compiled gold-standard lists for both. Specifically, we took the union of 5 different curated lists of drivers that have been reported before, including the widely used Cancer Gene Census list [47] , a manually curated list of driver genes affected by copy number alterations [48] , genes annotated as oncogenes by UniProt [49] , a gene list derived from the Vogelstein 20/20 rule [11] , and a gene list derived from literature mining [50] (Supplementary Table 1 ). Passenger genes were defined by taking the union of two manually curated lists of known passengers from NCG4 [51] and Rubio-Perez et al. [52] (Supplementary Table 1) . These gold-standards are limited in that they are not cancer type or sample specific (though drivers are frequently shared [31, 53] and targeted [54] across cancer types), but represent an attempt to construct as comprehensive a list as possible such that novel cancer driver genes can be more effectively demarcated. The methods were evaluated on how well their predictions identified cancer driver genes based on three standard measures (as well as others as detailed below): precision (fraction of predictions that belong to the gold standard), recall (fraction of the gold standard contained in the predictions) and the F1 score that combines both precision and recall (see Methods for a more detailed description).
Due to the wide variation in the number of driver predictions from different methods (median of 10 for MutSigCV to >8,000 for MutationTaster; Supplementary Figure 3 Figure 7b) , highlighting the fact that many more driver genes remain to be discovered, and consistent with recent work showing that more driver genes exist even in extensively studied TCGA cancer types [13] .
We used the F1 score that combine precision and recall to rank methods and compare them against a "baseline" method that simply orders genes based on mutation frequency ( To evaluate how the driver predictions are affected by cohort size, we tested the different methods for robustness and power using a subsampling approach that compares predictions for a method to those on the full dataset (stability = precision and recovery = recall compared to results from full dataset; see Methods) [10] . Many methods exhibited high stability (>70%) at least for the 50 and 
Most methods predict no drivers for 10% of patients but many provide robust patient-specific predictions
We next evaluated methods for their ability to accurately identify driver events in a patient-specific manner to assess their utility for precision medicine applications. Note that not all methods provide predictions per patient and for such methods, we assumed that nominated driver genes are drivers in all patients in which they were mutated. We began by computing statistics for the number of drivers nominated in each patient by various methods, under the assumption that reporting too few (<1) or too many drivers (>15) may make them less useful (Figure 3a ; number of drivers per patient is generally expected to be <10 [1, 55, 56] ). Interestingly, with the exception of FI methods that call a large number of drivers for the majority of the patients, nearly all the other methods report no driver events for >10% of patients. This could be an indication of low sensitivity but could also be due to driver events having other origins (e.g. copy-number neutral rearrangements, large translocations, regulatory or noncoding mutations or methylation and other epigenetic events) that were not considered by these methods. The method OncoIMPACT was found to be unusual in this aspect (even compared to INA methods) as it identified at least 1 driver in nearly all patients. Methods belonging to the CBA and MEC categories typically identified <2 drivers in a large fraction of the cohorts (~40%). On the other end, some methods frequently (in >50% of cohort) identified >15 drivers in patients, suggesting that they may be overcalling at the patient-specific level To test robustness to noise and to estimate the specificity of the predictions at the patient-specific level, we introduced decoy passenger mutations in genes with probability weighted by the gene length (see Methods). Most methods exhibited good robustness to such noise with specificity generally higher than 95% (except for FI methods; Figure 3b and Supplementary Figure 14a) . In particular, methods in the FIC category accounted well in identifying decoy function altering mutations, improving significantly over methods in the FI category. Also, since CBA methods explicitly model such sources of noise, they were found to have the best control over them. We also noted that most patients (>80%) do not have any of the decoy mutations in their predictions even when the overall specificity of a method is ~95% (Figure 3b and Supplementary Figure 14b) . This is even more the case when only the top 5 or 10 predictions are considered, highlighting the robustness of many methods at the patient specific level. As summarized in Figure 3b , no single method uniformly outperformed the others at the patient-specific level as well.
Prioritization of actionable drivers is still a challenge for most individual methods
The prioritization of driver genes and mutations that are actionable is a key requirement for decision support systems to aid in precision oncology. We sought to evaluate the performance of the various methods studied here based on curated lists of actionable genes (genes that can be targeted by a drug under certain conditions) from the OncoKB [57] and IntOGen [52] databases (see Methods and Supplementary Table 2 ). Analyzing the top 5 driver predictions per patient from each method, we observed significant variability in performance, with the fraction of patients with a predicted actionable driver varying from 6% for OncodriveCIS to >60% for DriverNET and OncoIMPACT (Figure 4a ). We observed that the different methods provided largely non-overlapping predictions, enabling the union to predict actionable drivers for up to 81% of patients. A breakdown of the predictions by cancer type (Figure 4b) highlighted that six of them (LIHC, PRAD, KIRP, OV, KIRC, BRCA) have a much lower fraction of patients with predicted actionable driver genes. This could in part be due to the lack of sensitivity in driver prediction methods, but in most cases it is explained by the cancer types being enriched for non-targetable drivers, highlighting the need for further drug discovery efforts in these cancer types. Finally, as a positive control test, we assessed the sensitivity of the methods in predicting two known actionable oncogenes, BRAF (various drugs are FDA approved for treating melanoma with V600 mutations [58] ) and PIK3CA (the inhibitor alpelisib is currently undergoing a clinical trial for breast cancer [59] ) in patients harboring known oncogenic mutations (BRAF V600 and 19 PIK3CA mutations located in the domains of the catalytic subunit [57] , see Supplementary file 3). We observed notable variation in the numbers of patients where the mutations were flagged as drivers by different methods (Figure 4c) , with multiple methods that did not report the genes for any patient (similar results were observed with top 10 predictions; Supplementary Figure 15) . These results highlight that the differences in the underlying model of various methods can lead to dramatically different abilities in predicting actionable driver genes and that care should be exercised in interpreting and integrating results from different driver prediction systems.
Low concordance across methods enables the construction of a better consensus-based approach
A comparison of driver gene predictions across methods revealed that in addition to the expected differences across categories, many methods had a significant number of calls that were unique to them (Supplementary Figure 16a) . This was particularly the case for FIC methods such as fathmm and CHASM, and network based methods (INA) such as DawnRank, DriverNet and OncoIMPACT.
In addition, for the more sensitive methods (e.g. fathmm and OncoIMPACT), many predictions were shared by >4 methods suggesting that this could provide additional confidence for many of their calls. To evaluate if consensus approaches could improve over predictions from individual methods, we evaluated a rank-aggregation based approach [60] using all methods (BORDAall) as well as a subset of methods identified using cross-validation (ConsensusDriver; see Methods). We found that the same methods were consistently selected by ConsensusDriver across cancer types, covering a wide range of methods across categories (Figure 5b, Supplementary Figure 17 predicted driver genes is however lower, as many known driver genes are still not targetable (e.g.
Ovarian Cancer, where most patients harbor a TP53 mutation, exhibits the lowest fraction of patients with a predicted actionable gene).
Discussion
We provide the first systematic evaluation of different classes of driver prediction methods over a large number of cancer types. As the community still lacks standard evaluation protocols, we identified various criteria to evaluate predictions at the cancer-type level (concordance and sensitivity over know cancer genes, and stability/recovery of predictions upon sub-sampling) and at the patient-specific level (number of driver genes per patient, concordance with gold standard, robustness to noise mutations). The availability of our pre-formatted datasets, predictions from evaluated methods as well as a package of tools to study new predictions, provides a useful resource and a standardized framework to evaluate any newly developed method against a diverse panel of state-of-the-art methods and on a large number of cancer types. (e.g. miRNA-seq) and other mutation types (e.g. non-coding mutations).
Our study also provides a detailed analysis of the driver predictions at the patient level. It highlights the robustness (low false positive rate, high concordance with the gold standard) of the driver predictions, but also the lack of sensitivity (significant fraction of patients with 0 to 1 driver predicted) of the vast majority of methods, with methods integrating expression having the best performance. In terms of prioritizing actionable genes, most methods have even more severe limitations and integrating methods with different underlying models could help ameliorate this problem.
There are several limitations to our work: Firstly, we limited our analysis to a single data source (TCGA, which currently provides the most comprehensive coverage of cancer types with genomic and transcriptomic data) and to a set of well-cited methods with software implementations that we were able to use successfully. Secondly, our evaluations were based on gold-standard lists of driver genes that are not cancer-type or patient specific. They thus do not necessarily reflect the heterogeneity of cancers and lack direct evidence that a specific mutation has a functional role in a particular tumor. Other large-scale initiatives have tried to bridge this gap and provide cell-line specific shRNA (Achilles [62] ) and drug resistance profiles (CCLE [63] and GDSC [64] ). The results of these studies could potentially be used to generate more refined gold-standards. However, such analysis will not come without drawbacks as (i) the cell lines used typically do not have normal controls and thus mutation calls can be error-prone and (ii) the experiments are limited to measuring cell growth and thus miss other relevant phenotypes (e.g. motility, invasiveness etc.).
Nevertheless, large experimentally derived and patient specific gold-standard driver gene lists are needed to further advance the development and evaluation of new driver prediction methods.
Overall, our study highlights that while existing driver predictions methods can have limited sensitivity as a function of data-types and modeling assumptions used, their diversity in fact provides an avenue for better consensus methods, as demonstrated by the novel consensus method proposed here (ConsensusDriver). Development of methods that harness new sources of information thus might provide greater benefits then refinement of existing paradigms for driver discovery. From a practical point of view, we provide an easy-to-use package to run 18 different driver prediction methods, as well as to aggregate their results into consensus predictions that are largely superior to the individual methods, thus serving as a valuable toolbox for precision oncology efforts.
Material and Methods
Data source and preprocessing
CNA and exome point mutation data for all cancer types was obtained from GDAC via Firehose (https://gdac.broadinstitute.org). All point mutations excluding synonymous mutations (i.e. indels, missense, nonsense and splice site variants) and CNAs with a value of 2 (focal amplification) or െ 2 (focal deletion) were used for downstream analysis. Expression data for tumor and normal samples for all cancer types was downloaded from the TCGA website (level 3;
https://tcga-data.nci.nih.gov). For a detailed description of expression data analysis, see
Supplementary Methods.
Assessment of driver prediction methods
For each method, we used default parameters or the set of recommended parameters provided in the method's manual or corresponding publication. In cases where methods required a threshold for candidate driver selection (e.g. on the p-value or score for candidates), we used the value indicated in the method's publication or manual (see Supplementary Methods for a detailed description of the parameters and threshold used).
For analysis of patient-specific predictions, for most methods, mutated genes in each patient (with mutation types matching the expected input for the method) were ordered according to their rank on the full dataset. For FI and FIC methods, and for OncoIMPACT, mutation/patient specific scores were used to order genes (best score in the case of multiple mutations; ties broken by average gene score).
DriverDB predictions were obtained from http://driverdb.tms.cmu.edu.tw/driverdbv2/cancer.php and are based on the output of the following methods: ActiveDriver [36] , Netbox [44] , OncodriveFM [34] , MutSigCV [31] , Dendrix [43] , MDPFinder [65] , Simon [66] and MEMo [67] .
Genes predicted by 2 or more methods were selected and ranked using the order provided on the DriverDB website. MutSig predictions were obtained from Lawrence et al [13] .
A few methods were excluded from this benchmark for the following reasons: (i) they could not be run without further data processing, complex pre-filtering steps or inclusion of additional data (Genome MuSiC [32] , Conexic [38] , Mutex [42] and MultiDendrix [43] ), (ii) they had prohibitively high computational requirements (PARADIGM-SHIFT [68] ) or (iii) provided incompatible predictions (Gistic2 [35] with region-level predictions).
Performance evaluation Comparison with gold standard
We assessed the performance of all methods against a gold standard list of cancer driver genes (union of Cancer Gene Census [47] , a manually curated list of CNA drivers [48] , oncogenes from 
and the F1 score that combines both precision and recall,
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Generation of decoy missense mutations
For each patient, we introduced ݊ false positive/decoy mutations, where ݊ = 2%, 5% or 10% of the number of mutations in a tumor. Point mutations were randomly placed in coding regions of un-mutated genes with probability proportional to the coding length and missense mutations were selected using annovar (to avoid bias against methods that cannot analyze nonsense or splice-site mutations). For consistency, this analysis was restricted to the 12 cancer types annotated using the hg19 genome (i.e. COAD, OV and READ samples, annotated using hg18, were excluded).
Construction of an actionable gene list
We downloaded gene lists from IntOGen (https://www.intogen.org/) and OncoKB 
ConsensusDriver method
ConsensusDriver is based on the Borda approach, where each gene was given a score equal to the sum over all methods of either its rank, if the gene was ranked, or the maximum number of predictions in that data set ‫,)ܯ(‬ if the gene was unranked.
Genes were then re-ranked according to this score. To select the best set of methods for a particular cancer type, we used the following procedure (equivalent to a leave-one-out): (1) exhaustively compute the Borda consensus score on the 262,125 possible method combinations; (2) select the method combination which obtained the best average combine score for the others 14 cancer types.
For the sample specific predictions, we integrated the patient specific-predictions of the six methods identified (fathmm, CHASM, OncodriveFM, MutSigCV, DriverNET and OncoIMPACT, Supplementary Figure 17) . BORDAall used all the methods in constructing a BORDA based ranking. Breakdown of patients according to their cancer type reveals a cluster of 6 cancer types (highlighted in grey rectangle) with a low fraction of patients with predicted actionable drivers (complete linkage hierarchical clustering using Euclidean distance) (c) Number of patients with a predicted actionable driver mutation for the genes BRAF and PIK3CA. 2a.
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